Intranasal Inoculation of Cationic Crosslinked Carbon Dots-Adjuvanted Respiratory Syncytial Virus F Subunit Vaccine Elicits Mucosal and Systemic Humoral and Cellular Immunity

Abstract

Respiratory syncytial virus (RSV) causes severe acute lower respiratory tract infections, especially in infants and the elderly. Developing an RSV vaccine that promotes a robust mucosal immune response is necessary to successfully prevent viral transmission and the development of severe disease. We previously reported that crosslinked carbon dots (CCD) may be an excellent adjuvant candidate for intranasal (IN) protein subunit vaccines. Considering the strong immunogenicity of RSV prefused F protein (preF), we prepared an IN RSV vaccine composed of the CCD adjuvant and the preF protein as antigen (CCD/preF) and evaluated the induced antigen-specific humoral and cellular immunity. We found that IN immunization with the CCD/preF vaccine elicited strong serum IgG responses and mucosal immunity, including secreted IgA antibodies, tissue-resident memory T (T_RM) cells, and antigen-specific B cells, which lasted for at least 1 year. In addition, a combination of intramuscular and IN immunization with CCD/preF vaccine induced stronger systemic and mucosal immunity. Together, this study proved the high immunogenicity of the CCD/preF vaccines and supported the university of the mucosal CCD adjuvant, supporting further development of the CCD/preF vaccine in larger animal models and clinical studies.

Keywords

respiratory syncytial virus (RSV) / intranasal vaccine / crosslinked carbon dot (CCD) / adjuvant / mucosal immunity

References

[1] D. Ogonczyk-Makowska, P. Brun, C. Vacher, et al., “Author Correction: Mucosal Bivalent Live Attenuated Vaccine Protects Against human Metapneumovirus and respiratory Syncytial Virus in Mice,” NPJ Vaccines 9, no. 1 (2024): 125.

[2] R. Lozano, M. Naghavi, K. Foreman, et al., “Global and Regional Mortality From 235 Causes of Death for 20 Age Groups in 1990 and 2010: A Systematic Analysis for the Global Burden of Disease Study 2010,” Lancet 380, no. 9859 (2012): 2095-2128.

[3] Y. Li, X. Wang, D. M. Blau, et al., “Global, Regional, and National Disease Burden Estimates of Acute Lower Respiratory Infections due to Respiratory Syncytial Virus in Children Younger Than 5 Years in 2019: A Systematic Analysis,” Lancet 399, no. 10340 (2022): 2047-2064.

[4] E. E. Walsh, G. Pérez Marc, A. M. Zareba, et al., “Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults,” The New England Journal of Medicine 388, no. 16 (2023): 1465-1477.

[5] Y. Xu, F. Sun, Z. Chuai, et al., “Cold-adapted Influenza Vaccine Carrying Three Repeats of a respiratory Syncytial Virus (RSV) Fusion Glycoprotein Epitope Site Protects BALB/c Mice and Cotton Rats Against RSV Infection,” Antiviral Research 229 (2024): 105960.

[6] C. A. Green, E. Scarselli, C. J. Sande, et al., “Chimpanzee adenovirus- and MVA-vectored respiratory Syncytial Virus Vaccine Is Safe and Immunogenic in Adults,” Science Translational Medicine 7, no. 300 (2015): 300ra126.

[7] J. L. Grieves, Z. Yin, A. Garcia-Sastre, et al., “A Viral-vectored RSV Vaccine Induces Long-Lived Humoral Immunity in Cotton Rats,” Vaccine 36, no. 26 (2018): 3842-3852.

[8] C. Bian, S. Liu, N. Liu, et al., “Influenza Virus Vaccine Expressing Fusion and Attachment Protein Epitopes of Respiratory Syncytial Virus Induces Protective Antibodies in BALB/c Mice,” Antiviral Research 104 (2014): 110-117.

[9] N. B. Halasa, “RSV Prevention—Breakthroughs and Challenges,” New England Journal of Medicine 389, no. 26 (2023): 2480-2481.

[10] T. J. Ruckwardt, “The Road to Approved Vaccines for Respiratory Syncytial Virus,” NPJ Vaccines 8, no. 1 (2023): 138.

[11] H. Gu, Y. Gao, S. Zhou, et al., “Bivalent Vaccine Platform Based on ca Influenza Virus Vaccine Elicits Protective Immunity Against Human Adenoviruses,” Antiviral Research 153 (2018): 78-84.

[12] A. Mullard, “FDA Approves mRNA-Based RSV Vaccine,” Nat Rev Drug Discovery 23, no. 7 (2024): 487.

[13] M. Vidal Valero, “‘A Good Day’: FDA Approves World's First RSV Vaccine,” Nature 617, no. 7960 (2023): 234-235.

[14] A. Papi, M. G. Ison, J. M. Langley, et al., “Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults,” New England Journal of Medicine 388, no. 7 (2023): 595-608.

[15] L. R. Baden, H. M. El Sahly, B. Essink, et al., “Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine,” New England Journal of Medicine 384, no. 5 (2021): 403-416.

[16] D. M. Skowronski and G. De Serres, “Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine,” The New England Journal of Medicine 384, no. 16 (2021): 1576-1577.

[17] A. Alu, L. Chen, H. Lei, Y. Wei, X. Tian, and X. Wei, “Intranasal COVID-19 Vaccines: From Bench to Bed,” EBioMedicine 76 (2022): 103841.

[18] M. S. Habibi, A. Jozwik, S. Makris, et al., “Impaired Antibody-mediated Protection and Defective IgA B-Cell Memory in Experimental Infection of Adults With Respiratory Syncytial Virus,” American Journal of Respiratory and Critical Care Medicine 191, no. 9 (2015): 1040-1049.

[19] B. S. Bleier, M. Ramanathan, and A. P. Lane, “COVID-19 Vaccines May Not Prevent Nasal SARS-CoV-2 Infection and Asymptomatic Transmission,” Otolaryngology-Head and Neck Surgery: Official Journal of American Academy of Otolaryngology-Head and Neck Surgery 164, no. 2 (2021): 305-307.

[20] P. V'Kovski, A. Kratzel, S. Steiner, H. Stalder, and V. Thiel, “Coronavirus Biology and Replication: Implications for SARS-CoV-2,” Nature Reviews Microbiology 19, no. 3 (2021): 155-170.

[21] T. Suzuki, A. Ainai, and H. Hasegawa, “Functional and Structural Characteristics of Secretory IgA Antibodies Elicited by Mucosal Vaccines Against Influenza Virus,” Vaccine 35, no. 39 (2017): 5297-5302.

[22] F. Dotiwala and A. K. Upadhyay, “Next Generation Mucosal Vaccine Strategy for Respiratory Pathogens,” Vaccines 11, no. 10 (2023): 1585.

[23] C. J. Y. Tsai, J. M. S. Loh, K. Fujihashi, and H. Kiyono, “Mucosal Vaccination: Onward and Upward,” Expert Review of Vaccines 22, no. 1 (2023): 885-899.

[24] W. Hong, H. Lei, D. Peng, et al., “A Chimeric Adenovirus-Vectored Vaccine Based on Beta Spike and Delta RBD Confers a Broad-spectrum Neutralization Against Omicron-Included SARS-CoV-2 Variants,” MedComm 5, no. 5 (2024): e539.

[25] H. Xu, L. Cai, S. Hufnagel, and Z. Cui, “Intranasal Vaccine: Factors to Consider in Research and Development,” International Journal of Pharmaceutics 609 (2021): 121180.

[26] K. J. Gonzalez, K. C. Yim, J. C. G. Blanco, M. S. Boukhvalova, and E. M. Strauch, “Systematic Computer-Aided Disulfide Design as a General Strategy to Stabilize Prefusion Class I Fusion Proteins,” Frontiers in Immunology 15 (2024): 1406929.

[27] M. Magro, V. Mas, K. Chappell, et al., “Neutralizing Antibodies Against the Preactive Form of Respiratory Syncytial Virus Fusion Protein Offer Unique Possibilities for Clinical Intervention,” PNAS 109, no. 8 (2012): 3089-3094.

[28] A. Krarup, D. Truan, P. Furmanova-Hollenstein, et al., “A Highly Stable Prefusion RSV F Vaccine Derived From Structural Analysis of the Fusion Mechanism,” Nature Communications 6 (2015): 8143.

[29] L. van der Fits, R. Bolder, M. Heemskerk-van der Meer, et al., “Adenovector 26 Encoded Prefusion Conformation Stabilized RSV-F Protein Induces Long-lasting Th1-biased Immunity in Neonatal Mice,” NPJ Vaccines 5, no. 1 (2020): 49.

[30] C. S. Cho, S. K. Hwang, M. J. Gu, et al., “Mucosal Vaccine Delivery Using Mucoadhesive Polymer Particulate Systems,” Tissue Engineering and Regenerative Medicine 18, no. 5 (2021): 693-712.

[31] G. Del Giudice, R. Rappuoli, and A. M. Didierlaurent, “Correlates of Adjuvanticity: A Review on Adjuvants in Licensed Vaccines,” Seminars in Immunology 39 (2018): 14-21.

[32] M. G. Alameh, I. Tombacz, E. Bettini, et al., “Lipid Nanoparticles Enhance the Efficacy of mRNA and Protein Subunit Vaccines by Inducing Robust T Follicular Helper Cell and Humoral Responses,” Immunity 54, no. 12 (2021): 2877-2892. e7.

[33] H. Lei, A. Alu, J. Yang, et al., “Cationic Crosslinked Carbon Dots-adjuvanted Intranasal Vaccine Induces Protective Immunity Against Omicron-included SARS-CoV-2 Variants,” Nature Communications 14, no. 1 (2023): 2678.

[34] C. Li, J. Huang, L. Yuan, et al., “Recent Progress of Emitting Long-wavelength Carbon Dots and Their Merits for Visualization Tracking, Target Delivery and Theranostics,” Theranostics 13, no. 9 (2023): 3064-3102.

[35] P. Pierrat, R. Wang, D. Kereselidze, et al., “Efficient in Vitro and in Vivo Pulmonary Delivery of Nucleic Acid by Carbon Dot-based Nanocarriers,” Biomaterials 51 (2015): 290-302.

[36] T. Feng, X. Ai, G. An, P. Yang, and Y. Zhao, “Charge-Convertible Carbon Dots for Imaging-Guided Drug Delivery With Enhanced in Vivo Cancer Therapeutic Efficiency,” ACS Nano 10, no. 4 (2016): 4410-4420.

[37] S. Li, Z. Guo, G. Zeng, Y. Zhang, W. Xue, and Z. Liu, “Polyethylenimine-Modified Fluorescent Carbon Dots as Vaccine Delivery System for Intranasal Immunization,” ACS Biomaterials Science and Engineering 4, no. 1 (2018): 142-150.

[38] H. Lei, A. Alu, J. Yang, et al., “Intranasal Administration of a Recombinant RBD Vaccine Induces Long-term Immunity Against Omicron-included SARS-CoV-2 Variants,” Signal Transduction and Targeted Therapy 7, no. 1 (2022): 159.

[39] J. O. Ngwuta, M. Chen, K. Modjarrad, et al., “Prefusion F-specific Antibodies Determine the Magnitude of RSV Neutralizing Activity in human Sera,” Science Translational Medicine 7, no. 309 (2015): 309ra162.

[40] M. K. Slifka and I. Amanna, “How Advances in Immunology Provide Insight Into Improving Vaccine Efficacy,” Vaccine 32, no. 25 (2014): 2948-2957.

[41] M. Broketa and P. Bruhns, “Single-Cell Technologies for the Study of Antibody-Secreting Cells,” Frontiers in Immunology 12 (2021): 821729.

[42] S. E. McGettigan and G. F. Debes, “Immunoregulation by Antibody Secreting Cells in Inflammation, Infection, and Cancer,” Immunological Reviews 303, no. 1 (2021): 103-118.

[43] L. Mesin, J. Ersching, and G. D. Victora, “Germinal Center B Cell Dynamics,” Immunity 45, no. 3 (2016): 471-482.

[44] P. S. Arunachalam, N. Ha, S. M. Dennison, et al., “A Comparative Immunological Assessment of Multiple Clinical-stage Adjuvants for the R21 Malaria Vaccine in Nonhuman Primates,” Science Translational Medicine 16, no. 758 (2024): eadn6605.

[45] P. A. Szabo, M. Miron, and D. L. Farber, “Location, Location, Location: Tissue Resident Memory T Cells in Mice and Humans,” Science Immunology 4, no. 34 (2019): eaas9673.

[46] K. D. Zens, J. K. Chen, and D. L. Farber, “Vaccine-generated Lung Tissue-resident Memory T Cells Provide Heterosubtypic Protection to Influenza Infection,” JCI Insight 1, no. 10 (2016): e85832.

[47] N. Lam, Y. Lee, and D. L. Farber, “A Guide to Adaptive Immune Memory,” Nature Reviews Immunology 24, no. 11 (2024): 810-829.

[48] R. A. Karron, C. Luongo, J. S. Mateo, K. Wanionek, P. L. Collins, and U. J. Buchholz, “Safety and Immunogenicity of the Respiratory Syncytial Virus Vaccine RSV/ΔNS2/Δ1313/I1314L in RSV-Seronegative Children,” Journal of Infectious Diseases 222, no. 1 (2020): 82-91.

[49] P. Spearman, H. Jin, K. Knopp, et al., “Intranasal Parainfluenza Virus Type 5 (PIV5)-vectored RSV Vaccine Is Safe and Immunogenic in Healthy Adults in a Phase 1 Clinical Study,” Science Advances 9, no. 43 (2023): eadj7611.

[50] C. F. Yang, C. K. Wang, E. Malkin, et al., “Implication of respiratory Syncytial Virus (RSV) F Transgene Sequence Heterogeneity Observed in Phase 1 Evaluation of MEDI-534, a Live Attenuated Parainfluenza Type 3 Vectored RSV Vaccine,” Vaccine 31, no. 26 (2013): 2822-2827.

[51] S. Ascough, I. Vlachantoni, M. Kalyan, et al., “Local and Systemic Immunity Against Respiratory Syncytial Virus Induced by a Novel Intranasal Vaccine. A Randomized, Double-Blind, Placebo-controlled Clinical Trial,” American Journal of Respiratory and Critical Care Medicine 200, no. 4 (2019): 481-492.

[52] R. A. Karron, C. Luongo, B. Thumar, et al., “A Gene Deletion That Up-regulates Viral Gene Expression Yields an Attenuated RSV Vaccine With Improved Antibody Responses in Children,” Science Translational Medicine 7, no. 312 (2015): 312ra175.

[53] B. Bagga, J. E. Cehelsky, A. Vaishnaw, et al., “Effect of Preexisting Serum and Mucosal Antibody on Experimental Respiratory Syncytial Virus (RSV) Challenge and Infection of Adults,” Journal of Infectious Diseases 212, no. 11 (2015): 1719-1725.

[54] A. R. Falsey, P. A. Hennessey, M. A. Formica, C. Cox, and E. E. Walsh, “Respiratory Syncytial Virus Infection in Elderly and High-risk Adults,” New England Journal of Medicine 352, no. 17 (2005): 1749-1759.

[55] P. J. Watt, B. S. Robinson, C. R. Pringle, and D. A. Tyrrell, “Determinants of Susceptibility to Challenge and the Antibody Response of Adult Volunteers Given Experimental respiratory Syncytial Virus Vaccines,” Vaccine 8, no. 3 (1990): 231-236.

[56] A. M. W. Malloy, Z. Lu, M. Kehl, J. Pena DaMata, A. W. Lau-Kilby, and M. Turfkruyer, “Increased Innate Immune Activation Induces Protective RSV-specific Lung-resident Memory T Cells in Neonatal Mice,” Mucosal Immunology 16, no. 5 (2023): 593-605.

[57] E. Kinnear, L. Lambert, J. U. McDonald, H. M. Cheeseman, L. J. Caproni, and J. S. Tregoning, “Airway T Cells Protect Against RSV Infection in the Absence of Antibody,” Mucosal Immunology 11, no. 1 (2018): 249-256.

[58] N. Li, L. Zhang, B. Zheng, et al., “RSV Recombinant Candidate Vaccine G1F/M2 With CpG as an Adjuvant Prevents Vaccine-associated Lung Inflammation, Which May be Associated with the Appropriate Types of Immune Memory in Spleens and Lungs,” Human vaccines & immunotherapeutics 15, no. 11 (2019): 2684-2694.

[59] J. Fuchs, J. Hübner, A. Schmidt, et al., “Evaluation of Adenoviral Vector Ad19a Encoding RSV-F as Novel Vaccine Against Respiratory Syncytial Virus,” NPJ Vaccines 9, no. 1 (2024): 205.

[60] J. S. McLellan, M. Chen, M. G. Joyce, et al., “Structure-based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus,” Science 342, no. 6158 (2013): 592-598.

[61] L. Bian, Y. Zheng, X. Guo, et al., “Intramuscular Inoculation of AS02-Adjuvanted Respiratory Syncytial Virus (RSV) F Subunit Vaccine Shows Better Efficiency and Safety than Subcutaneous Inoculation in BALB/c Mice,” Frontiers in Immunology 13 (2022): 938598.

[62] D. Lapuente, J. Fuchs, J. Willar, et al., “Protective Mucosal Immunity Against SARS-CoV-2 After Heterologous Systemic Prime-Mucosal Boost Immunization,” Nature Communications 12, no. 1 (2021): 6871.

[63] M. Tiboni, L. Casettari, and L. Illum, “Nasal Vaccination Against SARS-CoV-2: Synergistic or Alternative to Intramuscular Vaccines?,” International Journal of Pharmaceutics 603 (2021): 120686.

[64] P. A. Jorquera, L. Anderson, and R. A. Tripp, “Understanding respiratory Syncytial Virus (RSV) Vaccine Development and Aspects of Disease Pathogenesis,” Expert Review of Vaccines 15, no. 2 (2016): 173-187.

[65] Y. Wang, F. Ge, J. Wang, et al., “Mycobacterium Bovis BCG Given at Birth Followed by Inactivated Respiratory Syncytial Virus Vaccine Prevents Vaccine-Enhanced Disease by Promoting Trained Macrophages and Resident Memory T Cells,” Journal of Virology 97, no. 3 (2023): e0176422.

[66] M. S. Russell, M. Creskey, A. Muralidharan, et al., “Unveiling Integrated Functional Pathways Leading to Enhanced Respiratory Disease Associated with Inactivated Respiratory Syncytial Viral Vaccine,” Frontiers in Immunology 10 (2019): 597.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.